Stockscreener 앱 받기
12.19
4.64%
0.54
시간 외 거래:
12.19
전일 마감가:
$11.65
열려 있는:
$11.63
하루 거래량:
773.74K
Relative Volume:
0.94
시가총액:
$637.25M
수익:
$88.24M
순이익/손실:
$-160.90M
주가수익비율:
-4.5755
EPS:
-2.6642
순현금흐름:
$-129.35M
1주 성능:
+13.40%
1개월 성능:
+4.19%
6개월 성능:
+30.37%
1년 성능:
+71.69%
1일 변동 폭
$11.26
$12.35
1주일 범위
$10.54
$12.35
52주 변동 폭
$5.97
$14.00
4D몰큘러 테라퓨틱스 Stock (FDMT) Company Profile
명칭
4 D Molecular Therapeutics Inc
전화
(510) 505-2680
주소
5858 HORTON STREET #455, EMERYVILLE
Compare FDMT vs VRTX, REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
FDMT
4 D Molecular Therapeutics Inc
|
12.19 | 620.52M | 88.24M | -160.90M | -129.35M | -2.6642 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
4D몰큘러 테라퓨틱스 Stock (FDMT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-28 | 재개 | Barclays | Overweight |
| 2025-11-07 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2025-01-13 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2024-11-21 | 개시 | Morgan Stanley | Underweight |
| 2024-09-23 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2024-04-15 | 개시 | Barclays | Overweight |
| 2024-02-07 | 재개 | Goldman | Buy |
| 2023-10-26 | 개시 | RBC Capital Mkts | Outperform |
| 2023-10-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-10-18 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2023-07-05 | 개시 | Chardan Capital Markets | Buy |
| 2023-01-30 | 개시 | BMO Capital Markets | Outperform |
| 2022-11-18 | 개시 | H.C. Wainwright | Buy |
| 2022-11-15 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-08-12 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2022-06-22 | 개시 | Jefferies | Buy |
| 2022-01-04 | 개시 | SVB Leerink | Outperform |
| 2021-01-05 | 개시 | BofA Securities | Buy |
| 2021-01-05 | 개시 | Evercore ISI | Outperform |
| 2021-01-05 | 개시 | Goldman | Neutral |
모두보기
4D몰큘러 테라퓨틱스 주식(FDMT)의 최신 뉴스
4DMT Announces New Employment Inducement Grants - The Manila Times
H.C. Wainwright reiterates Buy on 4D Molecular stock, $36 target By Investing.com - Investing.com Nigeria
4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
4D Molecular Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Is 4D Molecular Therapeutics Inc (FDMT) Undervalued After Q2 Ear - GuruFocus
4D Molecular Therapeutics (NASDAQ:FDMT) Announces Quarterly Earnings Results - marketbeat.com
FDMT (NASDAQ: FDMT) stockholder schedules 1,635-share sale after option exercise - Stock Titan
4D Molecular Therapeutics (FDMT) posts $141.7M first-half 2026 net loss - Stock Titan
4DMT Reports Second Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones - The Manila Times
Dimensional Fund Advisors LP Purchases 227,982 Shares of 4D Molecular Therapeutics, Inc. $FDMT - marketbeat.com
4D Molecular Therapeutics (FDMT) Short Interest & Short Float | Updated Aug 2026 - marketbeat.com
4D Molecular Therapeutics Inc (FDMT) Stock News Today - TradingKey
4D Molecular Therapeutics Inc (FDMT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
4D Molecular Therapeutics Inc expected to post a loss of $1.02 a shareEarnings Preview - TradingView
4D Molecular Therapeutics Inc (FDMT) Stock Price, Trades & News - GuruFocus
4D Molecular Therapeutics, Inc. (FDMT) insider sells 26,842 shares under plan - Stock Titan
Ken Fisher's 4D Molecular Therapeutics Inc(FDMT) Holding History - GuruFocus
4D Molecular Therapeutics (FDMT) Insider David Kirn Sells 12,415 Shares - GuruFocus
FDMT (FDMT) insider plans 26,842-share Class A sale after sizable prior trades - Stock Titan
David Kirn Sells 12,415 Shares of 4D Molecular Therapeutics (NASDAQ:FDMT) Stock - marketbeat.com
4D Molecular Therapeutics (FDMT) CEO sells 12,415 shares via 10b5-1 plan - Stock Titan
Enterprise value to revenue forward of 4D Molecular Therapeutics, Inc. – NASDAQ:FDMT - TradingView
Form 144 4D Molecular Therapeutics For: 4 August By Investing.com - Investing.com Nigeria
FDMT (FDMT) investor David Kirn plans Rule 144 sale of 12,415 shares - Stock Titan
Janus Henderson Group PLC Acquires 611,276 Shares of 4D Molecular Therapeutics, Inc. $FDMT - marketbeat.com
4D Molecular Therapeutics (NASDAQ:FDMT) Rating Increased to Strong-Buy at Chardan Capital - MarketBeat
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives Average Rating of "Moderate Buy" from Analysts - marketbeat.com
4D Molecular Therapeutics, Inc. Revenue Breakdown – NASDAQ:FDMT - TradingView
Exome Asset Management LLC Purchases New Position in 4D Molecular Therapeutics, Inc. $FDMT - marketbeat.com
4D Molecular Therapeutics Inc (FDMT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
4D Molecular Therapeutics Inc (FDMT) Income Statement - tradingkey.com
4D Molecular Therapeutics Inc (FDMT) Valuation: PE, PB & Fair Value Analysis - TradingKey
FDMT|4D Molecular Therapeutics Inc|Price:10.380|Chg%:+0.310 - TradingKey
4D Molecular Therapeutics Inc (FDMT) Balance Sheet - TradingKey
4D Molecular Therapeutics Inc (FDMT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
4D Molecular Therapeutics Inc (FDMT) Institutional Confidence - TradingKey
4D Molecular Therapeutics Inc (FDMT) Cash Flow - TradingKey
4D Molecular Therapeutics Inc - TradingKey
4D Molecular Therapeutics Inc (FDMT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
FDMT|4D Molecular Therapeutics Inc|Price:10.070|Chg%:-0.310 - TradingKey
4D Molecular releases phase 2 data for wet AMD asset 4D-150 - MSN
4D Molecular's one-shot eye therapy delivers two-year win - MSN
Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT) and Tempus AI, Inc. Class A (TEM) - The Globe and Mail
4D Molecular Therapeutics (FDMT) Reports Positive Phase 2 Results for AMD Treatment - GuruFocus
4D Molecular Therapeutics Posts Strong 4D-150 Trial Results - The Globe and Mail
4D Molecular Therapeutics reports positive 2-year Phase 2b PRISM data for 4D-150 in wet AMD - Bitget
symbol__ Stock Quote Price and Forecast - CNN
4D Molecular: 'Buy' Wet-AMD Study Readouts 2027 And DME Expansion Opportunity (FDMT) - Seeking Alpha
Why Is 4D Molecular Therapeutics Stock Gaining Monday?4D Molecular Therapeutics (NASDAQ:FDMT) - Benzinga
4D Molecular Therapeutics Reports Positive 2-Year Phase 2b Results for 4D-150 in Wet AMD, Shows Reduced Treatment Burden and Strong Safety Profile 5678 – Minichart - Minichart
4D Molecular Therapeutics (Nasdaq: FDMT) posts positive 2-year wet AMD data - Stock Titan
4D몰큘러 테라퓨틱스 (FDMT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.52%
0.07%
자본화:
|
볼륨(24시간):